Oxacillin sodium salt

A semisynthetic β-lactam antibiotic

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
100mg

￥537.00

430.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajce52170
CAS: 1173-88-2
别名: 苯唑西林钠
分子式: C19H18N3NaO5S
分子量: 423.42
纯度: >98%
溶解度: DMF: 20 mg/ml,DMSO: 16 mg/ml,Ethanol: 2 mg/ml,PBS (pH 7.2): 10 mg/ml
储存: Store at -20°C
库存: 现货

Background

Oxacillin is a semisynthetic β-lactam antibiotic.^1,2 It is active against clinical isolates of methicillin-susceptible S. aureus and penicillin-susceptible S. pneumoniae, as well as group A, group B, and viridans group streptococci with MIC₉₀ values ranging from 0.06 to 2 ?g/ml in vitro.³ Oxacillin is less effective toward other bacteria with MIC₉₀ values of greater than 16 ?g/ml for S. epidermidis, S. haemolyticus, E. faecalis, E. faecium, methicillin-resistant S. aureus (MRSA), and penicillin-intermediate and -resistant S. pneumoniae. It targets the bacterial cell wall, inhibiting S. pneumoniae penicillin-binding proteins 1a, 1b, 2a, 2b, and 3 in vitro with IC₅₀ values ranging from 0.17 to 1.75 ?M.^4,2 Oxacillin inhibits growth of S. aureus in a thigh model of infection in mice (ED₅₀ = 45.19 mg/kg, s.c.).⁵ Formulations containing oxacillin have been used in the treatment of susceptible bacterial infections.

1.Hawks, G.H.Antibiotic therapy of staphylococcal infectionCan. Med. Assoc. J.93(16)848-853(1965) 2.Williamson, R., Hakenbeck, R., and Tomasz, A.In vivo interaction of β-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniaeAntimicrob. Agents Chemother.18(4)629-637(1980) 3.Milatovic, D., Schmitz, F.J., Verhoef, J., et al.Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolatesAntimicrob. Agents Chemother.47(1)400-404(2003) 4.Balibar, C.J., Shen, X., McGuire, D., et al.cwrA, a gene that specifically responds to cell wall damage in Staphylococcus aureusMicrobiology156(Pt 5)1372-1383(2010) 5.Rodriguez, C.A., Agudelo, M., Zuluaga, A.F., et al.In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillinBMC Infect. Dis.10(153)(2010)